A hydroxyfattysulfonic acid analog represented by Formula (I): wherein X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH 2 or S(O)pCH 2 wherein p is 0, 1 or 2; m is an integer of 1 to 5 inclusive; n is an integer of 0 to 4 inclusive;R 1 is a C 1-8 alkyl group, a C 3-8 cycloalkyl group, a C 1-4 alkyl group substituted with a C 3-8 cycloalkyl group, a C 1-4 alkyl group substituted with an aryl group or a C 1-4 alkyl group substituted with an aryloxy group; R 2 is a hydrogen atom or a methyl group; R 1 and R 2 together with the carbon atom to which they are attached may form a C 3-8 cycloalkyl group; R 3 is a hydrogen atom or a C 2-8 acyl group; R 4 is OR 5 or NHR 6 , wherein R 5 is a hydrogen atom, a C 1-4 alkyl group, an alkali metal, an alkaline earth metal or an ammonium group and R 6 is a hydrogen atom or a C 1-4 alkyl group; or a pharmaceutically acceptable salt or a hydrate thereof. The compounds of the present invention are useful as an elastase release inhibitor.